Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Seleaina Thomas

Nurse Practitioner, Family Victorville, CA Nurse Practitioner

NPI 1871790444 CMS profile 11173123

16850 Bear Valley Rd, Victorville, CA 92395

Open in the dashboard

General payments

$7,312

291 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Seleaina Thomas of Victorville, CA is reported in the CMS Open Payments database as having received $7,312 across 291 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,084 119
2024 General $1,584 69
2023 General $1,141 57
2022 General $1,503 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Seleaina Thomas
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Seleaina Thomas were reported at $3,084. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Seleaina Thomas Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $1,503 $141 $44–$430 $149
2023 $1,141 $154 $49–$476 $160
2024 $1,584 $165 $51–$504 $164
2025 $3,084 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Amgen Inc. $1,600 69 payments
  2. AbbVie, Inc. $1,215 44 payments
  3. UCB, Inc. $727 23 payments
  4. Mallinckrodt Hospital Products Inc. $686 25 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $632 30 payments
  6. GlaxoSmithKline, LLC. $422 21 payments
  7. Lilly USA, LLC $388 5 payments
  8. Vision Quest Industries Inc. $235 14 payments
  9. ANI Pharmaceuticals, Inc. $222 13 payments
  10. Pfizer Inc. $205 8 payments
  11. Other $981 39 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $7,042 287 payments
  2. Consulting Fee $175 1 payment
  3. Education $92 2 payments
  4. Travel and Lodging $3 1 payment
Products named General payments · program years 2022–2025
  1. ACTHAR $686 25 payments
  2. RINVOQ $669 31 payments
  3. Kerendia $632 30 payments
  4. Bimzelx $613 18 payments
  5. Otezla $568 29 payments
  6. KRYSTEXXA $487 19 payments
  7. Enbrel $366 21 payments
  8. BENLYSTA $352 16 payments
  9. Repatha $296 10 payments
  10. Prolia $257 9 payments
  11. Other $3,049 118 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 79 drugs

Part D claims

5,609

Median for Nurse Practitioner: 389

Drug cost

$11,795,260

Median for Nurse Practitioner: $21,885

Branded share of claims

42.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 454 $3,262,792
Acthar Corticotropin Brand 36 $3,036,354
Enbrel Sureclick Etanercept Brand 173 $1,311,907
Rinvoq Upadacitinib Brand 167 $1,081,910
Cosentyx Sensoready Pen Secukinumab Brand 31 $458,377
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 17 $458,336
Benlysta Belimumab Brand 78 $382,056
Evenity (2 Syringes) Romosozumab-Aqqg Brand 128 $316,876
Orencia Clickject Abatacept Brand 50 $288,870
Xeljanz Xr Tofacitinib Citrate Brand 29 $173,174

The 10 drugs with the highest cost, of 79 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ACTHAR
  • Mallinckrodt Hospital Products Inc. $337
$337 36 —
RINVOQ
  • AbbVie, Inc. $218
$218 167 —
SKYRIZI
  • AbbVie, Inc. $182
$182 — —
Otezla
  • Amgen Inc. $112
$112 — —
Enbrel
  • Amgen Inc. $112
$112 173 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

291 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record